← All trials
NCT05009966
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 16, 2021
- Primary completion
- Dec 31, 2023
- Completion date
- Jun 30, 2024
- First posted
- Aug 18, 2021
- Last posted
- Oct 25, 2021
- Enrollment
- 272
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shijiazhuang Pharma Group (CSPC)Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.